Replies to post #4791 on GTC Biotherapeutics (fka GTCB)

[kris_kade]

The more I read these #'s off of pre-clinical trials of AT in DIC indications, I cannot help but realize the Leo's PII trail got to be successful.

"In a more recent study where 35 patients with DIC associated with severe sepsis received high doses of AT versus placebo, a 44% reduction in mortality was shown in the AT group8.
In a recent retrospective analysis of the KyberSept trial in patients with sepsis and DIC, a clear reduction of 28 and 90 days mortality was shown within patients with DIC as compared to patients without DIC. At 28 days, there was 25.4% mortality among the patients treated with antithrombin compared to 40% mortality for those patients that received a placebo. At 90 days, there was 34.3% mortality among antithrombin treated patients compared to 50.4% mortality among patients treated with a placebo "